Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H4)
抗体来源（Source）
Monoclonal Anti-IFNγ Antibody, Human IgG1 (13E6H4) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
克隆号（Clone）
13E6H4
种属（Species）
Mouse
亚型（Isotype）
Human IgG1 | Human Kappa
偶联（Conjugate）
Unconjugated
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Human
免疫原（Immunogen）
Recombinant Human IFNγ derived from HEK293 cells
特异性（Specificity）
This product is a specific antibody specifically reacts with IFN-γ, Human. No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.
应用（Application）
Application | Recommended Usage |
ELISA | 0.1-100 ng/mL |
纯度（Purity）
95% as determined by SDS-PAGE.
纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
重构方法（Reconstitution）
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
关键字： IFNγ抗体;IFNγ;重组抗体;百普赛斯;ACRO;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。